All In Biotech

Drug Trial Radar · NCT06279286

Phase Ⅰb/Ⅱ Study of HS-10506 in Chinese Participants With Insomnia Disorder

A Randomized, Double-blind, Placebo-controlled Phase Ⅰb/Ⅱ Study to Investigate the Safety, Tolerability, Pharmacokinetics and Efficacy of HS-10506 in Chinese Adult Participants With Insomnia Disorder

Last checked: Nov 19, 2026Latest source record: Apr 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 312 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

312

Planned (sponsor's estimate)

Start

May 2024

Primary completion

Jan 2025

Study completion Jan 2025

Sponsor

Sponsor type
Industry
First posted
Feb 28, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this phase Ⅰb/Ⅱ study is to investigate the safety, tolerability, pharmacokinetics (the study of the way a drug enters and leaves the blood and tissues over time) after multiple dose administration and the efficacy of HS-10506 (change versus placebo) on latency to persistent sleep (LPS) measured by polysomnography (PSG) in Chinese adult participants with insomnia disorder.

Conditions

  • Insomnia Disorder

Interventions

  • HS-10506Drug

    HS-10506, tablets (10mg, 20mg, 40mg and 80mg) at night once daily from Day 1 to Day 5 in phase Ib study, and from Day 1 to Day 28 in phase II study.

  • PlaceboDrug

    Placebo, placebo tablets matching the HS-10506 tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of adverse events (AE)Time frame: Baseline up to the end of the study (3 days after the last dose) or early withdrawal
  2. Incidence and severity of serious adverse events (SAE)Time frame: Baseline up to the end of the study (3 days after the last dose) or early withdrawal
  3. Changes in laboratory test before and after drug administrationTime frame: Baseline up to the end of the study (3 days after last dose) or early withdrawal
  4. Changes in ECG before and after drug administrationTime frame: Baseline up to the end of the study (3 days after last dose) or early withdrawal
  5. Changes in Karolinska Sleepiness Scale (KSS) scores before and after drug administrationTime frame: From start of the drug administration to the next day of the last dose or early withdrawal
  6. Change from baseline in the mean LPS measured by PSG on Night 13 and Night 14Time frame: Baseline, Night 13& Night 14

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Xuanwu Hospital Capital Medical University

    Beijing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.